Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start - Episode 7
HIV Drug Resistance Testing Practices and Patient Education
Experts on HIV provide clinical insights on testing for drug resistance prior to treatment and approaching the topic of resistance with patients.
BIC = bictegravir
DRV = darunavir
DTG = dolutegravir
F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide
F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate
B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)
DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)
D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)
CAB = Cabotegravir
CAB + RPV = Cabotegravir + Rilpivirine
Video content above is prompted by the following question:
- How has resistance in HIV treatment changed over the years?
- FDA approvals have provided options for those with resistance.
- How do you test for HIV drug resistance prior to treatment?
- How do you monitor for development of resistance?
- How you determine to stay on current treatment or switch therapies?
- long acting injectables vs oral treatments
- protection against resistance
- What recommendations do you have for physicians and advanced practice providers in the community setting?
